HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raised the price target from $26 to $30.
August 12, 2024 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Catalyst Pharmaceuticals and raised the price target from $26 to $30.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Catalyst Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100